. Author manuscript; available in PMC: 2011 Aug 1.

Published in final edited form as: J Thorac Cardiovasc Surg. 2010 Apr 15;140(2):440–446. doi: 10.1016/j.jtcvs.2010.03.002

Table 2. Pulmonary function at the end of the 120-min reperfusion period.

Group	PA Pressure (mm Hg)	Compliance (cm H₂O)	Oxygenation (mm Hg)
Control	32.83 ± 0.48	4.93 ± 0.03	527.7 ± 1.1
A₁ agonist	24.17 ± 1.19 ^a^, ^d	5.70 ± 0.03 ^a^, ^b	551.7 ± 2.2 ^a^, ^b
A₁ agonist + antagonist	31.67 ± 0.56 ^b	5.07 ± 0.03 ^b	527.0 ± 2.1
A_2A agonist	18.50 ± 0.62 ^a^, ^c^, ^d	5.87 ± 0.08 ^a^, ^b	569.2 ± 1.1 ^a^, ^b^, ^c^, ^d
A_2A agonist + antagonist	31.33 ± 0.84 ^b	5.12 ± 0.48 ^b	525.3 ± 2.9 ^b
A₃ agonist	29.17 ± 1.66 ^b^, ^c	5.85 ± 0.04 ^a^, ^b	556.2 ± 4.0 ^a^, ^b
A₃ agonist + antagonist	32.00 ± 1.59 ^b	5.07 ± 0.06 ^b	530.0 ± 3.5
Adenosine	21.67 ± 0.49 ^a	5.33 ± 0.04 ^a	538.3 ± 2.5 ^a

p<0.0002 vs. Control,

p<0.02 vs. Adenosine,

p<0.01 vs. A₁ agonist,

p<0.02 vs. A₃ agonist